BioPharma Dive March 25, 2024
As precision medicine expands into a growing number of therapeutic areas, yesterday’s “one size fits all” approach to drug development is becoming less common. Instead, targeted patient populations for new therapies are shrinking, a trend that’s expected to continue as pharmaceutical and biotech companies race to pursue—and eliminate—the largest opportunities first. In this rapidly evolving landscape, sponsors need to think carefully about how to commercialize each precision medicine therapy’s companion diagnostic (CDx) if they want to maximize their new treatment’s chances of success.
Historically speaking, pharmaceutical sponsors have tended to underinvest in CDx commercialization. This lack of investment has had a major negative impact on how quickly new precision medicine therapies could reach the right patients, delaying access to potentially...
Today's Sponsors
Today's Sponsor